A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
Latest Information Update: 24 Feb 2025
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Melphalan
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms DETERMINATION; DFCI 10-106
Most Recent Events
- 12 Feb 2025 According to Dana-Farber Cancer Institute media release, the study will be presented at the 2025 Tandem Meetings
- 06 Jan 2025 Planned End Date changed from 1 Sep 2025 to 1 Dec 2026.
- 12 Dec 2023 Results of an exploratory analysis assessing outcomes with RVd-alone vs RVd+ASCT in AA and White patients from two clinical trials: DETERMINATION and GRIFFIN presented at the 65th American Society of Hematology Annual Meeting and Exposition